Oncologia
Estudo internacional, prospectivo e observacional | Efeitos das instalações hospitalares sobre os desfechos do paciente após cirurgia oncológica.
16 Jun, 2022 | 12:53h
Comentário no Twitter (fio – clique para saber mais)
Global impact of hospital facilities on patient outcomes after cancer surgery from @globalsurg 3, published in @LancetGH
For every 100 #cancer operations, one to three early surgical deaths could be saved with improvements to hospital resources worldwidehttps://t.co/Qiv5dSZPzb pic.twitter.com/EbSInePjI4
— Steve Knight (@sr_knight1) May 30, 2022
Sob licença de Creative Commons Attribution (CC BY 4.0)
Estudo de coorte | Qualidade de vida de longo prazo em pacientes com câncer de mama após conservação da mama vs. mastectomia e reconstrução.
16 Jun, 2022 | 12:47hLong-term Quality of Life in Patients With Breast Cancer After Breast Conservation vs Mastectomy and Reconstruction – JAMA Surgery (link para o resumo – $ para o texto completo)
Comentários:
Long-Term QOL Examined for Surgical Choices in Breast Cancer – HealthDay
Comentário no Twitter
Survey of #breastcancer survivors after treatment found:
1. Breast satisfaction and physical well-being similar with lumpectomy+rads or mastectomy+reconstruction (no rads)
2. Psychosocial well-being and sexual well-being better with lumpectomy+rads https://t.co/tPh9Pt4gYx— JAMA Surgery (@JAMASurgery) April 14, 2022
Estudo randomizado | Furmonertinibe vs. gefitinibe como terapia de primeira linha para pacientes com câncer de pulmão de não pequenas células localmente avançado ou metastático positivo para mutação EGFR.
16 Jun, 2022 | 12:02hFurmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study – The Lancet Respiratory Medicine (link para o resumo – $ para o texto completo)
Estudo randomizado | Tremelimumabe com durvalumabe em carcinoma hepatocelular irressecável.
16 Jun, 2022 | 12:01hTremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma – NEJM Evidence
Comentário no Twitter
Durvalumab plus a single dose of tremelimumab increased overall survival by just over 2.5 months in patients with unresectable hepatocellular carcinoma who had not received previous systemic therapy. Read more about the HIMALAYA trial by @GABOUALFA et al.: https://t.co/8d2qp54OLt pic.twitter.com/AA1RlSEP2a
— NEJM Evidence (@NEJMEvidence) June 6, 2022
Estudo randomizado | Abiraterona e olaparibe para câncer de próstata metastático resistente à castração.
16 Jun, 2022 | 12:00hAbiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer – NEJM Evidence
Comentário no Twitter
Combination treatment with abiraterone and olaparib increased progression-free survival regardless of homologous recombination repair gene mutation status in patients with metastatic castration-resistant #ProstateCancer treated in the first-line setting. https://t.co/CAUDF2ZErG pic.twitter.com/YARZa8AUXJ
— NEJM Evidence (@NEJMEvidence) June 3, 2022
Estudo randomizado fase 2 | FOLFOXIRI (ácido folínico, 5-fluorouracila, oxaliplatina e irinotecano) antecipada com bevacizumabe com ou sem atezolizumabe no tratamento de pacientes com câncer colorretal metastático.
16 Jun, 2022 | 11:58hUpfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial – The Lancet Oncology (link para o resumo – $ para o texto completo)
Comentário no Twitter
In phase II AtezoTRIBE study of the addition of atezolizumab to first-line FOLFOXIRI + bevacizumab improved PFS in pts with pMMR/MSS mCRC (median 13.1 vs 11.5 months; adjusted HR 0.70, 80% CI 0.57–0.87; P = 0.018): https://t.co/0dkRxjvjsx #ImmunoOnc #CRCSM
— NatureRevClinOncol (@NatRevClinOncol) May 31, 2022
Estudo randomizado | Efeito do monitoramento eletrônico de sintomas nos desfechos relatados pelo paciente naqueles com câncer metastático.
14 Jun, 2022 | 14:03hEffect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial – JAMA (gratuito por tempo limitado)
Conteúdos relacionados:
Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial – Nature Medicine (se o acesso a este link for pago, tente este)
Key components of successful digital remote monitoring in oncology – Nature Medicine
Revisão sistemática | Testes para sangue oculto nas fezes à base de guáiaco vs. testes imunoquímicos para rastreamento de câncer colorretal em indivíduos com risco médio.
14 Jun, 2022 | 13:48h
Comentário no Twitter
💩 Which faecal blood test is more accurate in detecting #bowelcancer and large polyps in population screening? https://t.co/U2mLfk7ARo This systematic review looks at the evidence from 63 studies including almost 4 million individuals. @CochranePH @CCGlobalAgeing @CochraneCRC pic.twitter.com/xQeeADgHql
— The Cochrane Library (@CochraneLibrary) June 7, 2022
DNA cirulante de tumor como biomarcador em pacientes com tumor de Wilms estágios III e IV.
14 Jun, 2022 | 13:33hComentário: Analysis of Circulating Tumor DNA as a Biomarker in Stage III and IV Wilms Tumor – The ASCO Post
Estudo de coorte | Incidência do diabetes tipo 2 de início recente após câncer.
14 Jun, 2022 | 13:28hIncidence of New-Onset Type 2 Diabetes After Cancer: A Danish Cohort Study – Diabetes Care
Comunicado de imprensa: Cancer Increases the Risk of Developing Diabetes – University of Copenhagen
Comentários no Twitter
We identify several cancers as risk factor for T2D with associated ↑21% risk of death as consequence. Fantastic cross-disciplinary collaboration @CASTLE_research @FessorC @FrederikPersson @NEXSKU @BiomedUCPH @ADA_DiabetesPro @Rigshospitalet @Stenodiabeteshttps://t.co/LYDsDXSGNB pic.twitter.com/PdOZffSjFf
— Lykke Sylow (@LykkeSylow) June 2, 2022
Patients with cancer are at higher risk for developing diabetes (esp patients with pancreatic cancer (HR 5.00), brain tumours (HR 1.54) and uterine cancer (HR 1.41) https://t.co/FzjepMrENA pic.twitter.com/PWDs5xsHOn
— K Pavithran (@drkpavithran) June 3, 2022